Frequently Asked Questions About BioGuard UVC™ Medical UV Mask Technology
What is BioGuard UVC™?
BioGuard UVC™ is a medical UV mask device that uses patented UVC disinfection technology to neutralize respiratory pathogens in real-time. It is a wearable ultraviolet pathogen-inactivation platform designed for hospital infection prevention and respiratory infection control.
How does BioGuard UVC™ work?
BioGuard UVC™ uses a patented spiral UV chamber design that exposes exhaled air to germicidal UVC light at 254nm wavelength. This inactivates 99.9999% of respiratory pathogens including viruses, bacteria, TB, and measles.
How is BioGuard UVC™ different from traditional masks?
Unlike N95 masks and surgical masks that filter or trap pathogens, BioGuard UVC™ actively kills pathogens using UVC light. It is filter-free, does not restrict breathing, is over 100 times more effective, is pathogen agnostic, and prevents re-inhalation of concentrated pathogens.
What pathogens does BioGuard UVC™ inactivate?
BioGuard UVC™ is pathogen agnostic and inactivates all respiratory pathogens including COVID-19, influenza, pneumonia, tuberculosis (TB), measles, RSV, and other airborne infectious diseases. The medical UV mask achieves a 99.9999% pathogen inactivation rate.
Is BioGuard UVC™ FDA approved?
BioGuard UVC™ is pending FDA clearance as a class II, De Novo medical device. The technology is protected by U.S. Patent 12,343,572 and European Patents EP4126257 and EP4364817.
What is the market opportunity for hospital infection prevention?
Hospital Acquired Infections (HAIs) represent a $20 billion problem in the U.S. alone. With 15 million annual Emergency Department visits for respiratory infections, the U.S. market opportunity for BioGuard UVC™ is $3 billion.
© 2026 Geared Power BioTech, Inc. | U.S. Patent 12,343,572 | EP4126257 | EP4364817